coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Healthy Crawley PCN, Crawley · Health Inequalities Profile

    PCN U14816 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    51,930

    Registered population

    60.8% aged 18–64

    17.7%

    Aged 65+

    ICB 21.9% · England 17.9%

    21.4%

    Ethnic minority (non-White)

    12.1% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    7,177

    Hypertension register

    -0.36% in 3 yrs · England +5.60%

    405

    SMI register

    31.8% of Crawley's

    820

    COPD register

    Reviews -3.80% in 3 yrs

    Forecast to 2030

    7,520

    Hypertension patients, 2030

    +343 on today

    77.1%

    QRISK ≥20% on statins, 2030

    +6.64pp over 3 yrs

    4.5%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    79.9%
    Pre-school MMR2 and booster coverage trail.

    Age-five MMR2 is 79.9% (15.1 pp below the 95.0% target) and 4-in-1 booster is 78.7%; Woodlands&clerklands Partnership MMR2 is 66.1%.

    61.3%
    High-risk lipid therapy lags alongside higher unit cost.

    QRISK ≥ 20% lipid therapy is 61.3% (Crawley 65.9%, England 63.6%), while lipid-modifying items cost £2.90 (£69,773 more than at England's £1.86).

    76.8%
    Strong hypertension control and improving SMI checks.

    Hypertension treatment to target reaches 76.8% (England 70.3%) with 95.8% BP recording, while SMI BMI checks rose +14.5 pp to 84.9%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ reach 17.7% alongside a 21.4% ethnic minority resident share

    Across 51,930 registered patients, 17.7% (9,212) are aged 65+ (Crawley 13.7%, NHS Sussex Integrated Care Board 21.9%, England 17.9%). Children aged 0-17 comprise 21.5% (Crawley 22.1%, ICB 17.7%, England 19.6%). Census data for associated areas shows a 21.4% ethnic minority resident share, including 12.1% Asian or Asian British residents (Crawley 15.4%, ICB 3.7%, England 9.6%), reaching 16.0% at Ifield Medical Practice and 13.8% at Furnace Green Surgery, alongside 78.6% White residents (Crawley 73.4%, ICB 91.0%, England 81.1%). Projected list growth to 2030 is 3.2% under an unverified methodology.

    Age profile

    0–1721.5%
    18–6460.8%
    65+17.7%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White78.6%
    Asian12.1%
    Mixed3.7%
    Black3.5%
    Other2.0%

    Older people · falls rows are Crawley local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Crawley LA)2,5742,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)89.5%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)61.0%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Crawley LA)1,2059819552024/25
    Falls deaths, all ages, per 100,000 (Crawley LA)12.614.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    With 0.0% Core20 patients, health inequalities work centres on non-LSOA inclusion cohorts

    Healthy Crawley PCN records 0.0% of registered patients in Core20 quintile 1, below Crawley (1.3%), NHS Sussex Integrated Care Board (9.2%) and England (21.0%). The PCN average IMD decile is 6.2 (Crawley 5.1, NHS Sussex Integrated Care Board 6.1, England 5.5). Practice and PCN Core20 shares reconcile at 0.0% across all four practices (0 estimated residents). Practice IMD deciles range from 4.5 at Ifield Medical Practice to 7.3 at Pound Hill Medical Group. Inequalities work should therefore focus on non-LSOA inclusion cohorts rather than area-based outreach.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Woodlands&clerklands0.0% · 0 patients
    Ifield Medical0.0% · 0 patients
    Pound Hill0.0% · 0 patients
    Furnace Green0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    405

    SMI register

    0.76% recorded prevalence

    418

    Learning disability register

    0.79% recorded prevalence

    38

    Care homes, 734 beds

    In the PCN catchment

    8.7%

    Provide unpaid care

    Crawley, Census 2021

    The PCN records 418 learning disability patients (0.8%; Crawley 0.8%, ICB 0.6%, England 0.6%) and 405 severe mental illness patients (0.8%; Crawley 0.9%, ICB 1.1%, England 1.0%), comprising 35% and 31.8% of borough registers. Catchment data shows 38 care homes (734 beds), though occupancy is unverified. Substantial borough shares for learning disability and severe mental illness registers indicate significant inclusion health caseloads across primary care.

    Severe mental illness: physical health checks

    SMI checks reached 84.9% for BMI (England 82.1%) and 84.6% for blood pressure (England 83.4%). However, blood pressure recording stands at 75.3% at Ifield Medical Practice, leaving an uncompleted check gap.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,177

    Hypertension register

    −0.36%

    Register growth, 3 yrs

    Crawley +6.33% · England +5.60%

    +3.60pp

    BP control, under 80

    ≤140/90 · +0.80pp aged 80+

    +343

    More patients by 2030

    Forecast 7,520 (13.42%)

    Hypertension case-finding and control

    Hypertension blood pressure recording reached 95.8% (Crawley 93.2%, NHS Sussex Integrated Care Board 90.2%, England 90.0%) and treatment to target was 76.8% (Crawley 74.2%, NHS Sussex Integrated Care Board 69.1%, England 70.3%). Recorded QOF prevalence is 13.5% (7,177 patients; Crawley 13.8%, England 15.2%, NHS Sussex Integrated Care Board 16.3%). However, prevalence three-year change was -0.4%, while expanding in Crawley (+6.3%), NHS Sussex Integrated Care Board (+5.5%) and England (+5.6%). Crude prevalence is not age-adjusted. Strong blood pressure control alongside a contracting register may indicate unrecorded patients, which an opportunistic case-finding audit could test.

    Lipids and statins

    Patients with QRISK ≥ 20% treated with lipid lowering therapy is 61.3% (Crawley 65.9%, England 63.6%, NHS Sussex Integrated Care Board 60.0%). CKD patients treated with lipid lowering therapy reached 68.1% (England 70.3%, Crawley 69.9%, NHS Sussex Integrated Care Board 65.9%). Lower therapy coverage highlights scope to expand lipid prevention in high-risk groups.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202667,089£2.90£2.42£1.86£194,558
    Cardiovascular (all), 202591,143£3.55£3.32£3.33£323,558

    In 2026, lipid-modifying drugs cost £2.90 per item across 67,089 items (Crawley £2.34, NHS Sussex Integrated Care Board £2.42, England £1.86), representing £69,773 more than at England's unit cost. This difference is a unit-cost indicator rather than a savings target, reflecting prescribing choices across member practices.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +3.36%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.87%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 6.3% (3,128 patients; England 6.6%). Annual reviews reached 70.8% (England 65.7%), but varied from 49.6% at Ifield Medical Practice to 85.0% at Woodlands&clerklands Partnership, leaving a scale cohort of about 920 unreviewed patients. Meanwhile, COPD prevalence is 1.5% (820 patients; England 1.9%). While COPD reviews stand at 77.3% (England 76.4%), coverage fell 3.8% over three years (England +2.8%). Asthma prescribing for ages 5-19 is 1,101 per 1,000 (England 1,488).

    Cancer register and children's immunisation

    Cancer prevalence is 4.0% (2,122 patients; England 3.8%). Childhood immunisations show pre-school shortfalls: at age 5, 4-in-1 booster coverage is 78.7% (16.3 pp below the 95.0% target) and MMR dose 2 is 79.9% (15.1 pp below target; England 82.8%). MMR dose 2 ranges from 66.1% at Woodlands&clerklands Partnership to 96.0% at Furnace Green Surgery, with a 12 pp gap between doses at Pound Hill Medical Group.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months91.2%

    England 91.0%

    6-in-1 complete primary course at 24 months89.3%

    England 92.2%

    MMR dose 1 at 24 months86.4%

    England 88.3%

    MMR dose 2 at age 579.9%

    England 82.8%

    4-in-1 pre-school booster at age 578.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    In 2022, 58.5% of staged cancers across NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209 known-stage cases; England 55.3%), below the 75.0% national ambition by 16.5 pp. Known stage was recorded for 64.3% of registered cases (England 67.0%). Reaching 75.0% across the ICB would require about 1,360 additional early-stage diagnoses annually holding staged share fixed. In the PCN, breast screening coverage fell 2.5% over 2023 to 2024 (England +8.4%) to 69.2%. Cervical screening in women aged 25-49 fell 4.0% over 2023 to 2025 (England -1.0%) to 67.0%, with 62.2% at Ifield Medical Practice and 66.3% at Furnace Green Surgery.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), Surrey and Sussex Healthcare NHS Trust achieved 70.0% against the 85.0% 62-day cancer referral to treatment standard, below the standard by 15.0 pp (England 71.2%, NHS Surrey and Sussex Integrated Care Board 71.5%), behind Epsom and St Helier University Hospitals NHS Trust (86.8%) and ahead of University Hospitals Sussex NHS Foundation Trust (65.2%). The trust met the 28-day faster diagnosis standard at 77.7% (standard 75.0%, England 79.3%). In Jul 2026 diagnostics, 28.5% of patients at the trust waited 6+ weeks (England 23.1%), including echocardiography (43.8%) and non-obstetric ultrasound (32.3%).

    Pathways within standard (%)Surrey and Sussex HealthcareSussexEpsom and St HelierSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)77.7474.0189.7079.2979.32
    31-day treatment (96%)96.2076.7999.1690.4592.50
    62-day referral to treatment (85%)69.9765.2086.8271.5171.16
    Diagnostic waits over 6 weeks (%)Surrey and Sussex HealthcareSussexEpsom and St HelierEngland
    MRI27.535.620.3121.40
    CT18.498.571.069.92
    Echocardiography43.780.3925.4928.48
    Colonoscopy15.1139.3533.0130.83
    Gastroscopy21.0620.0230.9029.02
    All 15 DM01 tests28.5012.956.8323.14
    Community services activityWest Sussex residentsSurrey and Sussex ICB
    Care contacts78,050309,615
    Referrals16,01566,930
    Patients with a contact19,77085,660

    Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), community health services recorded 78,050 contacts for Crawley borough residents, with 56,740 contacts (72.7%) among adults aged 65 and over. These figures describe borough-level resident activity rather than PCN-registered patients. High older-adult community activity underscores coordinating borough community services with primary care.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Vaccination achievement spans 48.4 pp across practices despite uniformly high clinical QOF scores

    In 2025/26, QOF vaccination and immunisation achievement spanned 48.4 pp across captured practices, from 17.6% at Pound Hill Medical Group to 66.0% at Furnace Green Surgery (England 55.2%). Clinical-domain achievement was 98.4% at Ifield Medical Practice and 100.0% at Furnace Green Surgery (England 97.1%). This variation may reflect practice-level delivery differences.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Woodlands&clerklands950.066.5%77.1%85.1%
    Ifield Medical1150.074.1%71.8%84.7%
    Pound Hill1080.064.0%80.4%83.6%
    Furnace Green940.069.7%66.8%73.7%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNCrawleyAssetPCNCrawley
    Care homes (catchment)38 (734 beds)n/aSchools (catchment)91n/a
    Children's centres67Places of worship5145
    Libraries22Food banks (VCS)3no data
    Homelessness support (VCS)1no dataDay centres (VCS)61
    Children and young people (VCS)1no dataCarers support groups (VCS)11
    Primary schools (LA maintained)1710Primary academies1414

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Pre-school booster and MMR2 recall

    In Q1 2025/26, age-5 4-in-1 coverage was 78.7% (below the 95.0% target by 16.3 pp; England 80.9%) and MMR2 was 79.9% (below target by 15.1 pp; 6.9 pp below MMR1 at 86.8%). For discussion: standardise pre-school call-recall templates, audit children with MMR1 who lack MMR2, and test flexible clinic slots. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Option 2

    High-risk lipid therapy and formulary review

    QRISK ≥ 20% lipid therapy is 61.3% (Crawley 65.9%, England 63.6%) and CKD therapy is 68.1% (England 70.3%); 67,089 lipid-modifying items cost £2.90 each (£69,773 more than at England's £1.86 unit cost). For discussion: run a pharmacist-led search for untreated high-risk QRISK and CKD patients and review lipid-modifying formulary choices. Moderate effort to run.

    Option 3

    Dementia and stroke register coding audit

    Over 2023 to 2025, dementia prevalence fell 7.5% to 0.5% (274 patients; England +6.0%, 0.8%; range -46 to +132) and stroke fell 4.4% to 1.7% (924 patients; England +2.3%, 1.9%). For discussion: audit hospital discharge and care-home records for uncoded dementia or stroke diagnoses across member practices. Low cost, quick to run.

    Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.

    Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Culturally tailored health outreach (p2)Asian / Asian BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Non-LSOA clinical outreach strategy (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall audit (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension case finding audit (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school immunisation call and recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Digital access and website review (p9)GPPS easy to contact the practice using its website10YHP, hospital to communityPractice
    Option 1 · Pre-school booster and MMR2 recall (p12)4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Option 2 · High-risk lipid therapy and formulary review (p12)Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026—PCN
    Option 3 · Dementia and stroke register coding audit (p12)Dementia register · Dementia: QOF prevalence · Stroke register66.7% diagnosis ambition · 95% care plan 2027 · Core20PLUS5 CVD · CVDPREVENT · SSNAPPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15